- Home
- SANG vs LCTX Comparison
SANG vs LCTX Comparison
Compare SANG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- LCTX
- Stock Information
- Founded
- SANG 1984
- LCTX 1990
- Country
- SANG Canada
- LCTX United States
- Employees
- SANG N/A
- LCTX N/A
- Industry
- SANG Computer Software: Programming Data Processing
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SANG Technology
- LCTX Health Care
- Exchange
- SANG Nasdaq
- LCTX Nasdaq
- Market Cap
- SANG 235.6M
- LCTX 110.2M
- IPO Year
- SANG 2021
- LCTX N/A
- Fundamental
- Price
- SANG $7.01
- LCTX $0.55
- Analyst Decision
- SANG
- LCTX Strong Buy
- Analyst Count
- SANG 0
- LCTX 5
- Target Price
- SANG N/A
- LCTX $4.80
- AVG Volume (30 Days)
- SANG 7.6K
- LCTX 2.9M
- Earning Date
- SANG 02-06-2025
- LCTX 03-06-2025
- Dividend Yield
- SANG N/A
- LCTX N/A
- EPS Growth
- SANG N/A
- LCTX N/A
- EPS
- SANG N/A
- LCTX N/A
- Revenue
- SANG $244,406,000.00
- LCTX $8,719,000.00
- Revenue This Year
- SANG $3.36
- LCTX N/A
- Revenue Next Year
- SANG $7.39
- LCTX $41.15
- P/E Ratio
- SANG N/A
- LCTX N/A
- Revenue Growth
- SANG N/A
- LCTX N/A
- 52 Week Low
- SANG $2.50
- LCTX $0.48
- 52 Week High
- SANG $7.20
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- SANG 57.08
- LCTX 47.26
- Support Level
- SANG $6.89
- LCTX $0.51
- Resistance Level
- SANG $7.15
- LCTX $0.60
- Average True Range (ATR)
- SANG 0.20
- LCTX 0.04
- MACD
- SANG -0.02
- LCTX 0.01
- Stochastic Oscillator
- SANG 51.28
- LCTX 53.85
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.